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Abstract 
  Indole-3-carbinol, found in Brassica sp. vegetables (such as cabbage, 
cauliflower, and brussels spouts), exhibits antitumor effects through poorly 
defined mechanisms. Because several genes that regulate apoptosis, proliferation, 
and metastasis are regulated by NF-κB, we postulated that indole-3-carbinol must 
mediate its activity through NF-κB modulation. We demonstrated that indole-3-
carbinol suppressed constitutive NF-κB activation and activation induced by TNF, 
IL-1β, PMA, LPS, and cigarette smoke; the suppression was not cell type specific, 
as activation was inhibited in myeloid, leukemia, and epithelial cells. This 
activation correlated with the sequential suppression of the IκBα kinase, IκBα 
phosphorylation, IκBα ubiquitination, IκBα degradation, p65 phosphorylation, p65 
nuclear translocation, and p65 acetylation and with NF-κB-dependent reporter 
gene expression.  The NF-κB-regulated gene products cyclin D1, COX-2, MMP-9, 
survivin, IAP1, IAP2, XIAP, Bcl-2, Bfl-1/A1, TRAF1, and FLIP were all 
downregulated by indole-3-carbinol. This downregulation led to the potentiation 
of apoptosis induced by cytokines and chemotherapeutic agents. Indole-3-carbinol 
suppressed constitutive NF-κB activation in mononuclear cells derived from bone 
marrow of acute myelogenous leukemia patients and this correlated with 
inhibition of cell growth.  Overall, our results indicated that indole-3-carbinol 
inhibits NF-κB and NF-κB-regulated gene expression and that this mechanism may 
provide the molecular basis for its ability to suppress tumorigenesis.  
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Introduction 
Indole-3-carbinol (I3C) is an autolysis product of a glucosinolate, 
glucobrassicin, found in Brassica sp. or cruciferous vegetables (cabbage, broccoli, 
cauliflower, and brussels spouts) 1,2. In vitro, I3C was found to suppress the 
proliferation of various tumor cells including breast 3, prostate 4, colon 5, and 
endometrial cancer cells.  In most cells, I3C induces G1/S cell cycle arrest 6. In vivo, 
I3C has been shown to suppress tumorigenesis of the colon 7,8, lung 9-11, breast 12, 
cervix 13,14 and liver 15.  
This molecule has been found to be effective clinically in treating 
precancerous lesions of the cervix and laryngeal papillomas, both of which have a 
human papillomavirus (HPV) component to there etiologies 16-19. I3C has also been 
shown to alter immune function 7,20, inhibit cigarette smoke-induced DNA-adduct 
formation 21, and reverse multidrug resistance in vivo. Rats fed I3C daily for 7 wk 
had significantly reduced natural killer cell activity and elevated T-cell-mediated 
delayed-type hypersensitivity but no change in antibody production 20.  
Numerous reports indicate that I3C mediates its effects through alteration of 
gene expression in different cells 22.  This indole downregulates the expression of 
various genes including inducible nitric oxide synthase (iNOS) 23, cyclin-
dependent kinase 6  (CDK6) 3,6, PSA 24, and Bcl-2 4.  It has also been shown to 
inhibit Akt 25 and CDK6 expression in human MCF-7 breast cancer cells by 
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disrupting Sp1 transcription factor interactions with a composite element in the 
CDK6 gene promoter 26. That I3C directly binds to estrogen receptor-alpha 27-30, 
aryl hydrocarbon (Ah) receptor 31, and androgen receptor 32 has been reported.  
Besides antiproliferative and immunomodulatory effects, I3C has also been 
demonstrated to suppress the invasion and migration of human breast cancer cells 
29,33.  
Although this wide range of activities has been assigned to I3C, its basic 
mechanism of action remains unclear.  Based on the confluence of pathways 
affected by I3C and NF-κB, we postulated that I3C interferes with the NF-κB 
activation pathway to exert its effects on gene expression.  For example, several 
genes that mediate proliferation, apoptosis, and metastasis are regulated by NF-κB 
34. This transcription factor is activated by various carcinogens and inflammatory 
stimuli, including cigarette smoke, TNF, IL-1, receptor of receptor activator of NF-
κB ligand (RANKL), phorbol 12-myristate 13-acetate (PMA), and 
lipopolysaccharide (LPS). NF-κB consists of p50 and p65 heterodimer retained in 
the cytoplasm by masking NLS by IκBα, the inhibitor. On activation, IκBα kinase 
(IKK) is activated, leading to IκBα phosphorylation, ubiquitination, and 
degradation; thus releasing p50-p65 to translocate to the nucleus, bind to its 
consensus sequence, and induce gene transcription.  Although NF-κB activation 
has been shown to regulate apoptosis and proliferation in leukemic cells 35-37, there 
is no report on the effect of I3C in these cells.  Therefore the aim of the current 
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From Takada et al  4/4/05  6 
study was to investigate the effect of I3C on the NF-κB activation pathway and on 
apoptosis in leukemic cells.  
 
Materials and Methods 
Reagents: I3C was purchased from Sigma-Aldrich (St. Louis, MO).  A 50 mM 
solution was prepared in dimethyl sulfoxide (DMSO; Sigma-Aldrich), stored as 
small aliquots at –20 oC, and then thawed and diluted as needed in cell culture 
medium as described 4,6. No loss of activity of I3C was noted after storage for six 
months. Throughout 0.1% DMSO (equivalent to 50 µM I3C) was used as control. 
Bacteria-derived human recombinant TNF, purified to homogeneity with a specific 
activity of 5 x 107
 
U/mg was kindly provided by Genentech (South San Francisco, 
CA). Bacteria-derived human recombinant IL-1β, purified to homogeneity with a 
specific activity of 1.0
 
EU/µg was purchased from R&D Systems (Minneapolis, 
MN). Cigarette smoke condensate (CSC), prepared as described 38, was kindly 
supplied by Dr. G. Gairola (University of Kentucky, Lexington, KY). Doxorubicin 
was kindly provided from Dr. Waldemar Priebe (M. D. Anderson Cancer Center, 
The University of Texas, Houston, TX).  Penicillin, streptomycin, RPMI 1640, 
IMDM, DMEM, nonessential amino acids, pyruvate, glutamine, vitamins, and FBS 
were obtained from Invitrogen (Grand Island, NY). PMA, LPS, okadaic acid, H2O2, 
cisplatin, anti-β-actin antibody, and basic chemical reagents were obtained from 
Aldrich-Sigma. Antibodies against p65, p50, IκBα, cyclin D1, MMP-9, PARP, IAP1, 
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IAP2, Bcl-2, Bfl-1/A1, and TRAF1 were obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA). Anti-COX-2 and anti-XIAP antibodies were obtained from BD 
Biosciences (San Diego, CA). Phospho-specific anti-IκBα (Ser32) and anti-acetyl-
lysine antibodies were purchased from Cell Signaling (Beverly, MA). Anti-IKK-α, 
anti-IKK-β, and anti-FLIP antibodies were kindly provided by Imgenex (San 
Diego, CA).  A polyclonal antibody that recognizes the serine 529 phosphorylated 
form of p65 was obtained from Rockland Laboratories (Gilbertsville, PA). N-acetyl-
leucyl-leucyl-norleucinal (ALLN) was purchased from Calbiochem (San Diego, 
CA). 
Cell lines: Jurkat (human T-cell leukemia), KBM-5 (human myeloid), H1299 
(human lung adenocarcinoma), U266 (human multiple myeloma), and SCC-4 
(human squamous cell carcinoma) cells were obtained from American Type 
Culture Collection.  MM.1 (human multiple myeloma) cells were kindly provided 
by Dr. Steven T. Rosen (Robert H. Lurie Comprehensive Cancer Center, Feinberg 
School of Medicine, Northwestern University, Chicago, IL).  KBM-5 cells were 
cultured in IMDM with 15 % FBS; Jurkat, H1299, MM.1, and U266 cells were 
cultured in RPMI 1640 medium with 10 % FBS; A293 cells were cultured in DMEM 
supplemented with 10 % FBS, and SCC-4 cells were cultured in DMEM containing 
10 % FBS, nonessential amino acids, pyruvate, glutamine, and vitamins.  All media 
were supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin. 
Clinical samples: Bone marrow specimens from AML patients with high (>70%) 
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From Takada et al  4/4/05  8 
blast counts (see Table 1) were obtained after signed informed content, according 
to institutional guidelines. Mononuclear cells were purified by Ficoll-Hypaque 
(Sigma-Aldrich) density-gradient centrifugation. 
Electrophoretic mobility shift assays (EMSA): To measure NF-κB activation, we 
prepared the nuclear extracts and performed EMSA as described previously 39. The 
dried gels were visualized, and radioactive bands quantitated by a 
PhosphorImager (Molecular Dynamics, Sunnyvale, CA) using Imagequant 
software.  
Western blot analysis: To determine the levels of protein expression in the 
cytoplasm or nucleus, we prepared extracts and fractionated them by SDS-
polyacrylamide gel electrophoresis (PAGE) as described previously 39. 
IKK assay: To determine the effect of I3C on IKK activation, IKK assay was 
performed by a method described previously 39. Briefly, whole-cell extract was 
prepared, incubated with anti-IKK-α antibody, and precipitated immunocomplex 
by protein A/G-Sepharose beads (Pierce, Rockford, IL). Immunocomplex was 
subjected for kinase assay using GST-IκBα (1-79) as substrate. 
NF-κB-dependent reporter gene expression assay: The effect of I3C on TNF- and 
TNFR1-induced NF-κB-dependent reporter gene transcription was analyzed by 
secretory alkaline phosphatase (SEAP) assay as described previously 39. Briefly, 
A293 cells were transiently transfected with the NF-κB-regulated SEAP reporter 
construct, incubated with I3C, and then stimulated them with TNF. Cells were also 
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cotransfected with TNFR1-expressing plasmids, and then NF-κB-dependent SEAP 
expression was monitored. 
Immunoprecipitation of p65 for p65 acetylation:  To determine the effect of I3C on 
TNF-induced acetylation of p65, was examined as described previously 40 . Briefly, 
whole-cell extract was prepared, incubated with anti-p65 antibody, and 
precipitated immunocomplex by protein A/G-Sepharose beads. Immunocomplex 
was subjected for SDS-PAGE, and performed Western blot analysis using anti-
acetyl-lysine antibody. 
Immunocytochemistry for NF-κB p65 localization: The effect of I3C on the nuclear 
translocation of p65 was examined by immunocytochemistry as described 
previously 39. Briefly, cells were fixed with parahormaldehyde, permeabilized with 
Triton-X 100, blocked with normal goat serum, incubated with rabbit polyclonal 
anti-p65 antibody, incubated with goat anti-rabbit IgG-Alexa 594 (Molecular 
Probes, Eugene, OR) and counterstained for nuclei with Hoechst 33342 (Sigma-
Aldrich). 
Cytotoxicity assay: The effect of I3C on the cytotoxic effects of TNF was 
determined by the MTT uptake method as described 41. Briefly, 5000 cells were 
seeded in triplicate in a 96-well plate and treated as indicated. Thereafter, an MTT 
solution was added, lysed, and then the OD was measured at 570 nm. 
TUNEL assay: We also assayed cytotoxicity by the terminal deoxynucleotidyl 
transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL) 
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method, as described previously 39. Briefly, cells were fixed with 
parahormaldehyde, permeabilized with Triton-X 100, and incubated with an in situ 
cell death detection reagent (Roche Applied Science, Indianapolis, IN). 
Live and dead assay: Apoptosis was measured by the Live and Dead assay 
(Molecular Probes), which determines intracellular esterase activity and plasma 
membrane integrity, was performed as described previously 39. 
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Results 
The current study was undertaken to investigate the effect of I3C on the 
NF-κB activation pathway, on NF-κB-regulated gene expression, and on apoptosis 
in leukemic cells. The concentration of I3C and NF-κB activators used and the time 
of exposure had minimal effect on the viability of these cells (data not shown).  
I3C blocks NF-κB activation induced by TNF, PMA, IL-1β, LPS, and cigarette 
smoke condensate.  Because TNF, IL-1β, PMA, LPS, and cigarette smoke 
condensate are potent activators of NF-κB, perhaps by different mechanisms 38,42,43, 
we examined the effect of I3C on the activation of NF-κB by these agents in Jurkat 
cells. Pretreatment of cells with I3C suppressed the activation of NF-κB induced by 
all five agents (Fig. 1A).  These results suggest that the I3C acts at a step in the NF-
κB activation pathway that is common to all five agents. 
I3C inhibits TNF-dependent NF-κB activation in a time-dependent manner. Since 
TNF is one of the most potent activators of NF-κB and the mechanism of activation 
of NF-κB is relatively well established, we examined the effect of I3C on TNF-
induced NF-κB activation. Jurkat cells were incubated with I3C for various times, 
and then exposed to TNF.  I3C by itself did not activate NF-κB but TNF-induced 
NF-κB activation was inhibited by I3C at 24 h (Fig. 1B). Under these conditions, 
cells treated with I3C were fully viable.  
Inhibition of NF-κB activation by I3C is dose-dependent and is not cell type 
specific.  Distinct signal transduction pathways can mediate NF-κB induction in 
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different cell types [for references see 44], so we also investigated whether I3C 
could block TNF-induced NF-κB activation in Jurkat, KBM-5, and H1299 cells. 
Cells were pretreated with different concentrations of I3C and then treated with 
TNF.  TNF activated NF-κB in all cell types, and I3C inhibited the activation in a 
dose-dependent manner (Fig. 1C). The results also indicate that 50 µM I3C is 
needed for maximum suppression of NF-κB activation.  
I3C inhibits constitutive NF-κB activation in a dose-dependent manner: 
  Whether I3C could suppress constitutive NF-κB activation was also 
examined.  We treated human multiple myeloma MM.1 and U266, and squamous 
cell carcinoma SCC-4 cells, which are known to express constitutive active NF-κB 
36,37,45 with various concentrations of I3C.  Constitutive NF-κB activation was 
suppressed above 50 µM (Fig. 1D). 
We have shown that high concentrations of TNF induce NF-κB more 
intensely than lower doses given for long times 46, so we decided to establish TNF 
dose effects for I3C inhibition. TNF at a concentration of 10 nM activated NF-κB 
activity strongly, however, cells pretreated with I3C abolished TNF-induced NF-κB 
activation (data not shown). These results show that I3C is a very potent inhibitor 
of TNF-induced NF-κB activation.  
  To determine whether I3C directly modifies the binding of NF-κB complex 
to the DNA, we incubated nuclear extracts from TNF-treated cells with various 
concentrations of I3C and then analyzed DNA binding activity by EMSA.  Our 
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results show that I3C did not modify the DNA-binding ability of the NF-κB 
complex (data not shown).  We conclude that I3C inhibits NF-κB activation 
through an indirect mechanism. 
Various combinations of Rel/NF-κB protein constitute active NF-κB 
heterodimers that bind to a specific DNA sequence 47.  To show that the retarded 
band visualized by EMSA in TNF-treated cells was indeed NF-κB, we incubated 
nuclear extracts from TNF-stimulated cells with antibodies to either the p50 (NF-
κB1) or the p65 (RelA) subunit of NF-κB. Both shifted the band to a higher 
molecular mass (data not shown), thus suggesting that the TNF-activated complex 
consisted of p50 and p65 subunits.  Neither preimmune serum nor the irrelevant 
antibody anti-cyclin D1 had any effect. Excess unlabeled NF-κB (100-fold) caused 
complete disappearance of the band, but a mutant oligonucleotide of NF-κB did 
not affect NF-κB binding activity.  
I3C inhibits TNF-dependent IκBα degradation. To determine whether I3C’s 
inhibitory activity was due to inhibition of IκBα degradation, we pretreated cells 
with I3C, exposed them to TNF for various times, and examined them for NF-κB 
activation in the nucleus by EMSA and for IκBα status in the cytoplasm by 
Western blot analysis. NF-κB was progressively activated with increase in 
incubation times with TNF. The I3C pre-treated cells showed a dramatic decrease 
in activation of NF-κB even after 60 min of TNF stimulation (Fig. 2A).   
The translocation of NF-κB to the nucleus is preceded by the proteolytic 
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degradation of IκBα 47.  We found that TNF induced IκBα degradation in control 
cells within 10 min, but in I3C-pretreated cells, TNF had no effect on IκBα 
degradation (Fig. 2B).  These results indicate that I3C inhibits both TNF-induced 
NF-κB activation and IκBα degradation.  
I3C inhibits TNF-dependent IκBα phosphorylation. To determine whether 
inhibition of TNF-induced IκBα degradation was due to inhibition of IκBα 
phosphorylation, we pretreated cells with I3C, exposed them to TNF for various 
times, and then examined them for IκBα phosphorylation status in the cytoplasm 
by Western blot analysis, using antibody that recognizes the serine-
phosphorylated form of IκBα.  Fig. 2C shows that TNF-induced IκBα 
phosphorylation was almost completely suppressed by I3C.  
I3C inhibits TNF-dependent IκBα  ubiquitination. Phosphorylation of IκBα by 
TNF leads to ubiquitination and degradation of IκBα 47. To investigate whether I3C 
affects TNF-induced IκBα ubiquitination, we performed Western blot analysis. We 
used the proteasome inhibitor ALLN to block the degradation of IκBα 48. TNF 
treatment alone slightly induced ubiquitination of IκBα, but when cells were 
pretreated with ALLN, TNF-induced ubiquitination of IκBα was enhanced (Fig. 
2D).  I3C almost completely suppressed IκBα ubiquitination induced by TNF, even 
in the presence of the proteasome inhibitor. 
I3C inhibits TNF-induced IKK activation.  It has been shown that IKK is required 
for TNF-induced phosphorylation of IκBα 47.  Since I3C inhibits the 
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phosphorylation of IκBα, we determined its effect on TNF-induced IKK activation.  
In immune complex kinase assays, TNF activated IKK as early as 5 min after TNF 
treatment but I3C completely suppressed this activation (Fig. 2E).  Neither TNF 
nor I3C had any effect on the expression of IKK-α or IKK-β proteins.  
To evaluate whether I3C suppresses the IKK activity directly by binding to 
the IKK protein or by suppressing the activation of IKK, we incubated whole-cell 
extracts from untreated and TNF-treated cells with various concentrations of I3C.  
Immunecomplex kinase assay showed that I3C did not directly bind IKK, 
suggesting that I3C modulates TNF-induced IKK activation (data not shown).   
I3C inhibits TNF-induced nuclear translocation of p65 in lymphoma cells. TNF 
induces the phosphorylation of p65, which is required for its transcriptional 
activity 49. Following phosphorylation, the p65 subunit is translocated to the 
nucleus.  As shown in Fig. 3A, TNF induced phosphorylation of p65 in a time-
dependent manner; as early as 5 min after TNF stimulation, p65 was 
phosphorylated and it levels in the cytoplasm increased up to 30 min. On 
pretreatment of cells with I3C, TNF failed to induce phosphorylation of p65.   We 
also showed that I3C suppressed TNF-induced nuclear translocation of p65 in a 
time-dependent manner (Fig. 3B).  
   The acetylation of p65 plays a key role in NF-κB transcriptional activity 50.  
To examine the effect of I3C on the acetylation of p65 by TNF, cells were pretreated 
with I3C and then treated with TNF for the indicated times.  Whole-cell extracts 
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were prepared and immunoprecipitated with anti-p65 antibody, and then Western 
blot analysis was performed using anti-acetyl-lysine antibody.  Whereas TNF 
induced acetylation of p65 in a time-dependent manner, I3C suppressed it (Fig. 
3C).  
An immunocytochemistry assay confirmed the effect of I3C on the 
suppression of nuclear translocation of p65: in untreated cells p65 localized in 
the cytoplasm, TNF induced its nuclear translocation, and I3C clearly 
suppressed this traslocation (Fig 3D).  
I3C represses TNF-induced NF-κB-dependent reporter gene expression. Though we 
have shown by EMSA that I3C blocks NF-κB activation, DNA binding alone does 
not always correlate with NF-κB-dependent gene transcription, suggesting that 
there are additional regulatory steps 51.  TNF-induced NF-κB activation is 
mediated through sequential interaction of the TNF receptor. To determine the 
effect of I3C on TNF-induced NF-κB-dependent reporter gene expression, we 
transiently transfected the cells with the NF-κB-regulated SEAP reporter construct, 
incubated them with I3C, and then stimulated them with TNF. Cells were also 
cotransfected with TNFR1-expressing plasmids, and then NF-κB-dependent SEAP 
expression was monitored. As shown in Fig. 4A, cells showed NF-κB-regulated 
reporter gene expression whether they were activated with TNF or transfected 
with TNFR1 plasmid, but I3C suppressed activation.  
I3C represses the TNF-induced NF-κB-dependent reporter gene products COX-2, 
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cyclin D1 and MMP-9. Whether I3C can modulate certain NF-κB-regulated gene 
products induced by TNF was also examined. That COX-2, cyclin D1, and MMP-9 
expression are regulated by NF-κB has been reported 34.  TNF has been shown to 
induce cyclin D1, COX-2 and MMP-9, which have NF-κB binding site in their 
promoter. Western blot analysis of whole-cell extracts showed that TNF induced 
cyclin D1, COX-2 and MMP-9 expression in a time-dependent manner and I3C 
blocked these expressions (Fig. 4B). The results further support the role of I3C in 
blocking TNF-induced NF-κB-regulated gene products.  
I3C represses TNF-induced NF-κB-dependent antiapoptotic gene products.  NF-κB 
regulates the expression of the anti-apoptotic proteins survivin, inhibitor-of-
apoptosis protein 1/2 (IAP1/2), X-chromosome-linked inhibitor-of-apoptosis 
protein XIAP, Bcl-2, Bfl-1/A1, TRAF1, and FLIP 34.  Whether I3C can modulate the 
expression of these anti-apoptotic gene products induced by TNF, was also 
examined. As shown in Fig. 4C, TNF induced these anti-apoptotic proteins in a 
time-dependent manner, and I3C blocked this induction.  
I3C potentiates apoptosis induced by TNF and chemotherapeutic agents.  The 
activation of NF-κB has been shown to inhibit TNF-induced apoptosis 52.  Above 
results suggest the potential of I3C in enhancing apoptosis induced by TNF and 
other cytotoxic agents through suppression of NF-κB-regulated anti-apoptotic gene 
products. Whether suppression of NF-κB by I3C affects TNF-induced apoptosis 
was investigated by MTT, PARP cleavage, Live and Dead assay, and TUNEL 
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staining methods.  I3C enhanced TNF-induced cytotoxicity (Fig. 5A1), as well as 
doxorubicin- (Fig. 5A2) and cisplatin-induced cytotoxicity (Fig. 5A3).  I3C by itself 
had little cytotoxic effect. Whether enhanced cytotoxicity was due to apoptosis was 
further investigated. As shown in Fig. 5B, TNF activated caspases as indicated by 
PARP-cleavage and I3C potentiated TNF-induced activity.  The Live and Dead assay 
indicated that I3C upregulates TNF-induced apoptosis from 7 % to 53 % (Fig. 5C), 
and TUNEL staining showed that TNF-induced apoptosis was enhanced from 8 % 
with TNF alone to 64 % with I3C plus TNF (Fig. 5D). In this assay I3C alone 
exhibited significant toxicity. Nevertheless, all assays together suggest that I3C 
enhanced the apoptotic effects of TNF and chemotherapeutic agents.  
I3C inhibits constitutive NF-κB activation and proliferation of mononuclear cells 
derived from AML patients.  It has been reported that NF-κB is constitutively 
active in AML cells 53 and that the active NF-κB mediates proliferation of cells 35.  
Whether I3C could suppress constitutively active NF-κB in AML cells was 
investigated in AML cells derived from ten different patients.  The cells were 
treated with I3C nuclear extracts were prepared, and then NF-κB activity was 
analyzed by EMSA.  As shown in Fig. 6A, NF-κB was found to be active in AML 
cells from most patients, to though variable extents, and I3C suppressed the 
activation.  We also found that the treatment of AML cells with I3C decreased the 
proliferation of cells (Fig. 6B).   
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Discussion 
  We found that I3C suppressed NF-κB activation induced by various agents 
irrespective of the cell type. NF-κB inhibition correlated with suppression of IKK 
and IκBα phosphorylation, ubiquitination, and degradation and with p65 
phosphorylation, nuclear translocation, and acetylation. I3C also downregulated 
NF-κB-regulated reporter gene transcription and gene products involved in cell 
proliferation, antiapoptosis, and invasion. This led to the potentiation of apoptosis 
induced by cytokines and chemotherapeutic agents (Fig. 7).  
I3C inhibited NF-κB activation induced by TNF, IL-1β, PMA, LPS, and CSC, 
suggesting that I3C must act at a step common to all of these activators. In response to 
most of these stimuli, NF-κB activation proceeds through sequential activation of IKK, 
phosphorylation at serines 32 and 36 of IκBα, and ubiquitination at lysines 21 and 22 of 
IκBα, leading finally to degradation of IκBα and the release of NF-κB 47.  We found that 
I3C blocks NF-κB activation by inhibiting IKK.   
Suppression of TNF-induced NF-κB activation by I3C is consistent with a 
report by Chinni et al., who showed the suppression of constitutive NF-κB in PC3 cells 
4. They did not, however, report how I3C suppressed constitutive NF-κB activation.  
Howells et al. found that the breast cancer cell lines MDA-MB468 and HBL-100 express 
constitutive NF-κB as examined by DNA binding and that treatment with I3C 
decreases DNA binding in MDA-MB468 cells and increases it in HBL-100 cells without 
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changing IKK activity in either cell line 54. They used up to a 20 times (1 mM) the 
concentration of I3C as we did to suppress NF-κB.  It is unlikely that these differences 
are due to cell type, as we found that I3C suppressed TNF-induced NF-κB activation in 
all cell types tested.  Perhaps the mechanism of constitutive NF-κB activation differs 
from that of inducible activation examined in our studies. 
Our studies are the first to indicate that I3C also inhibits TNF-induced IKK 
activation. How IKK is activated is not fully understood, but Akt has been implicated 
55, and I3C has been shown to suppress Akt activation 25,54. Thus it is possible that 
inhibition of TNF-induced IKK activation is due to inhibition of Akt.  The activation of 
Akt has also been shown to be involved in the phosphorylation of the p65 subunit of 
NF-κB 55. The suppression of p65 phosphorylation by I3C could also be due to 
inhibition of Akt.  
We showed that I3C inhibited NF-κB-regulated gene transcription and NF-κB-
regulated gene products involved in cell proliferation (e.g., cyclin D1 and COX-2); 
antiapoptosis (e.g., survivin, IAP1, IAP2, XIAP, Bcl-2, Bfl-1/A1, TRAF1, and FLIP) and 
invasion (MMP-9).  There is no previous report of the regulation of these gene products 
by I3C. That I3C downregulates cyclin D1 expression and the latter mediates G1/S 
transition may explain reports indicating that I3C induces of G1/S arrest 3,4. The 
downregulation of the expression of iNOS 23, PSA 12, and Bcl-2 4 could also be due to 
downregulation of NF-κB as described here. 
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We found that I3C potentiates the apoptotic effects of cytokines and 
chemotherapeutic agents through the downregulation of the antiapoptosis gene 
products survivin, IAP1, IAP2, XIAP, Bcl-2, Bfl-1/A1, TRAF1, and FLIP.  The cytotoxic 
effects of TNF, cisplatin, and doxorubicin were enhanced by I3C. These results are in 
agreement with a report that pretreatment with I3C augments TRAIL-induced 
apoptosis in the prostate cancer cell line LNCaP, as measured by PARP and caspase 3 
cleavage 56. Our results are also consistent with a report that an I3C acid-condensation 
product mixture sensitizes multidrug resistance gene transfectants to the toxicity of 
vinblastine and doxorubicin 57.  Whether enhancement of apoptosis by I3C is also 
mediated through this mechanism, in addition to downmodulation of NF-κB, is 
unclear at present.  
We also found that the expression of such NF-κB-regulated gene products 
as COX-2 and MMP-9 were downregulated by I3C. These results might explain the 
anti-invasive and antimetastatic activities assigned to I3C 33,58. Several chemokines, 
interleukins, and hematopoietic growth factors are regulated by NF-κB activation 
43. It is possible that immunomodulatory effects of I3C 7,20 are mediated through 
the regulation of these cytokines. I3C has been found to prevent cervical cancer in 
human HPV16 transgenic mice 13. Because a functional NF-κB binding site exists in 
the HPV16 long control region 59, it is possible that its effects against cervical 
cancer are mediated through suppression of NF-κB as described here. 
Constitutively active NF-κB has also been positively correlated with HPV16 E7 
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level in laryngeal squamous cell carcinoma 60. Through suppression of NF-κB, I3C 
may also be effective against this cancer. 
Given the pharmacological safety of I3C (established through centuries of 
dietary intake), our studies suggest that this compound has great potential as both 
a chemopreventive and a chemotherapeutic agent, especially when used in 
combination with existing agents.  Whether the concentrations of I3C used in our 
studies are achievable in vivo remains to be determined. How I3C is metabolized in 
the cells is also unclear at present. Our results also show that AML cells derived 
from patients exhibit constitutive NF-κB activation. This NF-κB activation is 
suppressed by I3C, thus leading to inhibition of proliferation of the cells. Overall, 
our results demonstrate that I3C is a potent inhibitor of NF-κB activation, which 
may explain its anti-proliferative, proapoptotic, anti-metastatic, anti-inflammatory, 
and immunomodulatory effects. 
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Table 1. Clinical data on patients 
Patient 
no. 
Source Type 
Sex 
Cytogenetic 
abnormality 
FAB 
Category 
Blast 
% 
Blasts in 
BM, % 
WBC count, 
x109/L 
1 BM  AML  M  Misc  M2  75  90  26.7 
2 BM  Leuk  M  t(8;21)      90  95  60.0 
3 BM  AML  M  +21  M2  74  85  32.0 
4 PB  AML  F  Misc  M4  92  95  24.7 
5 BM  Leuk  M Diploid  M5b 82  80  68.9 
6 BM  AML  M  t(9;22) Blast  Crisis  82  95  47.7 
7 BM  AML  F  Misc  M5b 85  45  106.1 
8 BM  AML  M  Misc  M4  85  95  60.5 
9 BM  AML  F  Misc  M4  90  90  116.7 
10 BM  AML  M  Pseudo-Diploid M0  71  45  32.6 
WBC indicates white blood cell; M, male; F, female; FAB, French-American-British; 
BM, bone marrow; PB, peripheral blood; Misc, miscellaneous. 
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Figure Legend 
Fig. 1. Effect of I3C on TNF-induced NF-κB activation. A. I3C blocks NF-κB 
activation induced by TNF, PMA, LPS, and CSC. Jurkat cells were preincubated 
with 50 µM I3C for 24 h, treated with 0.1 nM TNF and 10 µg/ml LPS for 30 min, 
100 ng/ml IL-1β, 15 ng/ml PMA, and 1 µg/ml cigarette smoke condensate (CSC) 
for 1 h, and then analyzed for NF-κB activation as described in Materials and 
Methods. B. Jurkat cells were preincubated at 37 oC with 50 µM I3C for the 
indicated times and then treated with 0.1 nM TNF at 37 oC for 30 min.  Nuclear 
extracts were then prepared and assayed for NF-κB activation by EMSA. Cell 
viability was determined by trypan blue dye exclusion method. C. I3C suppresses 
TNF-induced NF-κB in a dose-dependent manner in Jurkat, KBM-5 and H1299 
cells. Cells were incubated with different concentrations of I3C for 24 h, followed 
by an incubation with 0.1 nM TNF for 30 min.  Nuclear extracts were then 
prepared and assayed for NF-κB activation by EMSA. D. I3C inhibits constitutive 
NF-κB activation. MM.1, U266, and SCC-4 cells were incubated with different 
concentrations of I3C for 24 h.  Nuclear extracts were then prepared and assayed 
for NF-κB activation by EMSA. 
 
Fig. 2.  Effect of I3C on IκBα phosphorylation and degradation induced by TNF. 
A. I3C inhibits TNF-induced activation of NF-κB. Jurkat cells were incubated with 
50 µM I3C for 24 h, treated with 0.1 nM TNF for indicated times, and then 
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analyzed for NF-κB activation by EMSA.  B. Effect of I3C on TNF-induced 
degradation of IκBα. Jurkat cells were incubated with 50 µM I3C for 24 h and 
treated with 0.1 nM TNF for the indicated times.  Cytoplasmic extracts were 
prepared, fractionated on 10 % SDS-PAGE, and electrotransferred to nitrocellulose 
membrane.  Western blot analysis performed with anti-IκBα antibody. Anti-β-actin 
antibody was the loading control. C. Effect of I3C on the phosphorylation of IκBα 
by TNF.  Jurkat cells were incubated with of 50 µM I3C for 24 h and treated with 
0.1 nM TNF for the indicated times.  Cytoplasmic extracts were fractionated and 
then blotted using phospho-specific anti-IκBα antibody. D. Effect of I3C on TNF-
induced ubiquitination of IκBα.  Jurkat cells were pretreated with 50 µM I3C for 24 
h, then with 100 µg/ml of N-acetyl-leucyl-leucyl-norleucinal (ALLN) for 1 h, and 
finally with 0.1 nM TNF for 15 min.  Whole-cell extracts were prepared, 
fractionated, and examined by Western blot analysis using anti-IκBα antibody.  E. 
Effect of I3C on the activation of IKK by TNF.  Jurkat cells were incubated with 50 
µM I3C for 24 h and then activated with 1 nM TNF for different times.  Whole-cell 
extracts were immunoprecipitated with antibody against IKK-α and analyzed by 
immunocomplex kinase assay.  To examine the effect of I3C on the level of 
expression of IKK proteins, whole-cell extracts were fractionated on SDS-PAGE 
and examined by Western blot analysis using anti-IKK-α and anti-IKK-β 
antibodies.  
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Fig. 3.  Effect of I3C on the TNF-induced translocation of p65 into the nucleus. A. 
Western blot analysis of phospho-p65 and p65 using cytoplasmic extracts (CE).  
Jurkat cells were incubated with 50 µM I3C for 24 h and treated with 0.1 nM TNF 
for the indicated times in minutes.  Cytoplasmic extracts were prepared and 
subjected to Western blot analysis using anti-p65 antibody and phospho-specific 
anti-p65 antibody. B. Western blot analysis of phospho-p65 and p65 using nuclear 
extracts (NE). Jurkat cells were incubated with 50 µM I3C for 24 h and treated with 
0.1 nM TNF for the indicated times. Nuclear extracts were prepared and subjected 
to Western blot analysis using anti-p65 and phospho-specific anti-p65 antibodies. 
For loading control of nuclear protein, the membrane was blotted with anti-PARP 
antibody. C. Effect of I3C on TNF-induced acetylation of p65.  Jurkat cells were 
incubated with 50 µM I3C for 24 h and then treated with 1 nM TNF for the 
indicated times.  Whole-cell extracts were prepared, immunoprecipitated with 
anti-p65 antibody, and then examined by Western blot analysis using anti-acetyl-
lysine antibody. Whole-cell extracts were subjected to Western blot analysis using 
anti-p65 antibody. D. Immunocytochemical analysis of p65 localization after 
treatment with 1 nM TNF in the absence or presence of 50 µM I3C.  Jurkat cells 
were incubated with I3C for 24 h and then treated with 1 nM TNF for 30 min.  Cells 
were subjected to immunocytochemistry as described in Materials and Methods.  
 
Fig. 4. I3C inhibits the TNF-induced expression of NF-κB-dependent genes. A. 
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I3C inhibits the NF-κB-dependent reporter gene expression induced by TNF and 
TNFR1. A293 cells were transiently transfected with a NF-κB-containing plasmid 
alone or with TNFR1-expressing plasmids for 24 h. After transfection, cells were 
washed and treated with the indicated concentrations of I3C for 24 h.  For TNF-
treated cells, cells were washed and treated with 1 nM TNF for an additional 24 h.  
The supernatants of the culture medium were assayed for SEAP activity as 
described in Materials and Methods. B. I3C inhibits TNF-induced cyclin D1, COX-
2, and MMP-9 expression. Jurkat cells were incubated with 25 µM I3C and then 
treated with 1 nM TNF for the indicated times. Whole-cell extracts were prepared 
and analyzed by Western blot analysis using antibodies against cyclin D1, COX-2, 
and MMP-9. C. I3C inhibits the expression of TNF-induced anti-apoptotic proteins. 
Jurkat cells were incubated with 25 µM I3C and then treated with 1 nM TNF for the 
indicated times.  Whole-cell extracts were prepared and analyzed by Western blot 
analysis using antibodies against survivin, IAP1, IAP2, XIAP, Bcl-2, Bfl-1/A1, 
TRAF1, FLIP, and β-actin. 
 
Fig. 5. I3C enhances TNF-induced cytotoxicity. A. I3C enhances TNF- and 
chemotherapy-induced cytotoxicity. Five thousand Jurkat cells were seeded in 
triplicate in 96-well plates. Cells were pretreated with 1 µM I3C and then 
incubated with indicated concentrations of TNF, cisplatin, or doxorubicin for 
72 h. Thereafter, cell viability was analyzed by the MTT method as described 
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in Materials and Methods. B. Jurkat cells were pretreated with 25 µM I3C and 
then incubated with 1 nM TNF for the indicated times. Whole-cell extracts 
were prepared, subjected to SDS-PAGE, and blotted with anti-PARP antibody. 
C. Jurkat cells were pretreated with 25 µM I3C and then incubated with 1 nM 
TNF for 16 h. Cells were stained with Live and Dead assay reagent for 30 min 
and then analyzed under a fluorescence microscope as described in Materials 
and Methods. D. Jurkat cells were pretreated with 25 µM I3C and then 
incubated with 1 nM TNF for 16 h. Cells were fixed, stained with TUNEL 
assay reagent, and then analyzed under a fluorescence microscope as 
described in Materials and Methods. 
 
Fig. 6.  I3C inhibits constitutively active NF-κB activity and proliferation of AML 
cells.  A. 1 x 107 cells were resuspended in RPMI 1640 medium and treated with 50 
µM I3C for 24 h, and nuclear extracts were prepared and then analyzed for NF-κB 
activity by EMSA. B. 1 x 105 cells were in RPMI1640 were seeded in a 96-well plate, 
treated with the indicated concentrations of I3C for 72 h, and then analyzed for cell 
viability by the MTT method. 
 
Fig. 7.  A schematic diagram of the effect of I3C on TNF-induced NF-κB 
activation and apoptosis. 
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